Profile data is unavailable for this security.
About the company
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
- Revenue in USD (TTM)337.85m
- Net income in USD-522.66m
- Incorporated1999
- Employees558.00
- LocationGalapagos NVGeneraal De Wittelaan L11 A3MALINES (MECHELEN) 2800BelgiumBEL
- Phone+32 15342900
- Fax+32 15342901
- Websitehttps://www.glpg.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 43.69m | -715.54m | 1.85bn | 840.00 | -- | 1.67 | -- | 42.36 | -1.81 | -1.81 | 0.109 | 2.13 | 0.0411 | -- | 3.62 | 52,010.71 | -67.31 | -42.93 | -76.86 | -48.71 | -59.01 | -- | -1,637.81 | -828.92 | -- | -- | 0.0195 | -- | 32.00 | 90.93 | -41.33 | -- | 28.49 | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.93bn | 291.00 | -- | 5.91 | -- | 72.03 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.97bn | 122.00 | -- | 5.58 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.00bn | 78.00 | -- | 3.65 | -- | 648.85 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.11bn | 125.00 | -- | 5.57 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Soleno Therapeutics Inc | 98.68m | -78.45m | 2.13bn | 152.00 | -- | 4.30 | -- | 21.54 | -1.84 | -1.84 | 2.02 | 9.21 | 0.2201 | -- | -- | 1,072,554.00 | -17.50 | -59.81 | -18.49 | -66.17 | 98.14 | -- | -79.50 | -- | 15.88 | -- | 0.0915 | -- | -- | -- | -351.04 | -- | 59.68 | -- |
| Galapagos NV - ADR | 337.85m | -522.66m | 2.23bn | 558.00 | -- | 0.7634 | -- | 6.59 | -7.93 | -7.79 | 5.13 | 43.72 | 0.0747 | 1.02 | 6.32 | 479,898.10 | -11.55 | -2.04 | -12.74 | -2.28 | 84.31 | -- | -154.70 | -27.56 | 8.56 | -- | 0.0031 | -- | 14.99 | -20.82 | 67.85 | -- | 12.44 | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.23bn | 51.00 | -- | 3.86 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.33bn | 287.00 | -- | 16.41 | -- | 21.33 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.46bn | 627.00 | -- | 4.92 | -- | 10.25 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.51bn | 483.00 | -- | 2.59 | -- | 45.05 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Adaptive Biotechnologies Corp | 252.75m | -79.61m | 2.51bn | 619.00 | -- | 12.29 | -- | 9.95 | -0.5381 | -0.5381 | 1.65 | 1.34 | 0.4818 | 6.50 | 5.90 | 408,326.30 | -15.17 | -21.92 | -18.12 | -24.85 | 71.84 | 64.77 | -31.49 | -119.25 | 3.26 | -55.47 | 0.3923 | -- | 5.10 | 16.04 | 29.19 | -- | -20.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.56bn | 95.00 | -- | 6.66 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.64bn | 385.00 | -- | 35.84 | -- | 6.05 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
Data as of Feb 06 2026. Currency figures normalised to Galapagos NV's reporting currency: US Dollar USD
18.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 27 Oct 2025 | 4.29m | 6.52% |
| Madison Avenue Partners LPas of 30 Sep 2025 | 2.20m | 3.33% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 1.67m | 2.53% |
| Prosight Management LPas of 30 Sep 2025 | 1.15m | 1.75% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 1.02m | 1.54% |
| Segall Bryant & Hamill LLCas of 30 Sep 2025 | 487.20k | 0.74% |
| DME Capital Management LPas of 30 Sep 2025 | 482.75k | 0.73% |
| Point72 Asset Management LPas of 30 Sep 2025 | 443.87k | 0.67% |
| Threadneedle Asset Management Ltd.as of 30 Sep 2025 | 399.25k | 0.61% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 356.20k | 0.54% |
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
